Q32 Bio (QTTB) News Today $3.43 -0.07 (-2.00%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Leerink Partnrs Increases Earnings Estimates for Q32 BioDecember 15 at 1:41 AM | americanbankingnews.comQ32 Bio (NASDAQ:QTTB) Cut to "Hold" at Leerink PartnrsDecember 14, 2024 | americanbankingnews.comFY2025 EPS Estimates for Q32 Bio Raised by Leerink PartnrsQ32 Bio Inc. (NASDAQ:QTTB - Free Report) - Equities research analysts at Leerink Partnrs increased their FY2025 earnings per share estimates for shares of Q32 Bio in a research report issued to clients and investors on Wednesday, December 11th. Leerink Partnrs analyst T. Smith now forecasts thatDecember 13, 2024 | marketbeat.comQ32 Bio (NASDAQ:QTTB) Stock Rating Lowered by GuggenheimDecember 13, 2024 | americanbankingnews.comGuggenheim Downgrades Q32 Bio (QTTB)December 13, 2024 | msn.comLeerink Partnrs Downgrades Q32 Bio (NASDAQ:QTTB) to HoldLeerink Partnrs cut shares of Q32 Bio from a "strong-buy" rating to a "hold" rating in a report on Wednesday.December 12, 2024 | marketbeat.comWells Fargo Downgrades Q32 Bio (QTTB)December 12, 2024 | msn.comQ32 Bio (NASDAQ:QTTB) Stock, Short Interest ReportDecember 11, 2024 | benzinga.comInvestors Slaughter Q32 Bio On A 'Messy' Update In Eczema, Alopecia TreatmentDecember 11, 2024 | yahoo.comPiper Sandler Reaffirms Their Buy Rating on Q32 Bio (QTTB)December 11, 2024 | markets.businessinsider.comLeerink Partners Downgrades Q32 Bio (QTTB)December 11, 2024 | msn.comQ32 Bio (QTTB) Receives a Buy from OppenheimerDecember 11, 2024 | markets.businessinsider.comWhy Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?December 11, 2024 | benzinga.comQ32 Bio Shares Drop to New Low After Alopecia Drug Bempikibart Test ResultsDecember 11, 2024 | marketwatch.comQ32 Bio: Oppenheimer slashes price target on mixed trial resultsDecember 11, 2024 | msn.comQ32 Bio Stock Plunges After Analyst Downgrades, Price-Target Slashes Over Alopecia Data: Retail Confidence DropsDecember 11, 2024 | msn.comQ32 Bio Crashes 67% On A 'Messy' Update In Eczema, Alopecia TreatmentDecember 11, 2024 | investors.comOppenheimer Has Lowered Expectations for Q32 Bio (NASDAQ:QTTB) Stock PriceOppenheimer lowered their target price on shares of Q32 Bio from $80.00 to $20.00 and set an "outperform" rating on the stock in a report on Wednesday.December 11, 2024 | marketbeat.comLeerink Partners Reaffirms "Market Perform" Rating for Q32 Bio (NASDAQ:QTTB)Leerink Partners reissued a "market perform" rating and issued a $9.00 target price (down from $68.00) on shares of Q32 Bio in a report on Wednesday.December 11, 2024 | marketbeat.comRaymond James Reaffirms Outperform Rating for Q32 Bio (NASDAQ:QTTB)Raymond James reissued an "outperform" rating and set a $22.00 price target (down previously from $90.00) on shares of Q32 Bio in a report on Wednesday.December 11, 2024 | marketbeat.comWells Fargo & Company Reaffirms Equal Weight Rating for Q32 Bio (NASDAQ:QTTB)Wells Fargo & Company reissued an "equal weight" rating and issued a $16.00 price objective (down from $95.00) on shares of Q32 Bio in a research note on Wednesday.December 11, 2024 | marketbeat.comQ32 Bio (NASDAQ:QTTB) Price Target Lowered to $20.00 at Piper SandlerPiper Sandler dropped their price objective on Q32 Bio from $85.00 to $20.00 and set an "overweight" rating for the company in a research note on Wednesday.December 11, 2024 | marketbeat.comFmr LLC Purchases 246,664 Shares of Q32 Bio Inc. (NASDAQ:QTTB)Fmr LLC boosted its position in shares of Q32 Bio Inc. (NASDAQ:QTTB - Free Report) by 137.3% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 426,302 shares of the company's stock after buying an additional 246,664 shares duringDecember 11, 2024 | marketbeat.comQ32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development ProgramDecember 10, 2024 | prnewswire.comPoint72 Asset Management L.P. Purchases New Shares in Q32 Bio Inc. (NASDAQ:QTTB)Point72 Asset Management L.P. acquired a new stake in Q32 Bio Inc. (NASDAQ:QTTB - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 76,685 shares of the company's stock, valued at approximately $3,422,000. Point72 Asset Management L.December 9, 2024 | marketbeat.comBMO Capital Initiates Coverage of Q32 Bio (QTTB) with Outperform RecommendationDecember 6, 2024 | msn.comQ32 Bio (NASDAQ:QTTB) Coverage Initiated by Analysts at BMO Capital MarketsBMO Capital Markets assumed coverage on Q32 Bio in a report on Friday. They set an "outperform" rating and a $64.00 target price for the company.December 6, 2024 | marketbeat.comQ32 Bio Inc.'s (NASDAQ:QTTB) largest shareholders are private equity firms with 51% ownership, institutions own 30%December 4, 2024 | finance.yahoo.comQ32 Bio Inc. (NASDAQ:QTTB) Receives Consensus Rating of "Buy" from AnalystsQ32 Bio Inc. (NASDAQ:QTTB - Get Free Report) has been assigned an average rating of "Buy" from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The averagNovember 25, 2024 | marketbeat.comQ32 Bio (NASDAQ:QTTB) Trading Down 0.9% - Here's WhyQ32 Bio (NASDAQ:QTTB) Stock Price Down 0.9% - What's Next?November 22, 2024 | marketbeat.comPositive Outlook for Q32 Bio: Buy Rating Backed by Promising Clinical Timelines and Increased Price TargetNovember 11, 2024 | markets.businessinsider.comQ32 Bio Advances Clinical Trials Amidst Financial ChallengesNovember 9, 2024 | markets.businessinsider.comQ32 Bio Inc Grapples with Internal Control Challenges Amid Compliance CostsNovember 9, 2024 | markets.businessinsider.comQ32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 7, 2024 | prnewswire.comPositive Outlook for Q32 Bio: Buy Recommendation Supported by Promising Pipeline and De-risked Lead CandidateNovember 6, 2024 | markets.businessinsider.comQ32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation ConferenceNovember 5, 2024 | prnewswire.comQ32 Bio Inc. (NASDAQ:QTTB) Given Average Rating of "Buy" by BrokeragesQ32 Bio Inc. (NASDAQ:QTTB - Get Free Report) has been assigned an average recommendation of "Buy" from the seven brokerages that are presently covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating onOctober 31, 2024 | marketbeat.comQ32 Bio (NASDAQ:QTTB) Shares Down 3.6% - Time to Sell?Q32 Bio (NASDAQ:QTTB) Trading Down 3.6% - Here's What HappenedOctober 28, 2024 | marketbeat.comRaymond James Initiates Coverage of Q32 Bio (QTTB) with Strong Buy RecommendationOctober 26, 2024 | msn.comQ32 Bio (NASDAQ:QTTB) Trading Up 5% - Should You Buy?Q32 Bio (NASDAQ:QTTB) Trading Up 5% - What's Next?October 25, 2024 | marketbeat.comQ32 Bio (NASDAQ:QTTB) Receives New Coverage from Analysts at Raymond JamesRaymond James started coverage on Q32 Bio in a research note on Thursday. They set a "strong-buy" rating and a $90.00 price objective for the company.October 24, 2024 | marketbeat.comOppenheimer Maintains Bullish Stance on Q32 Bio with Robust Clinical OutlookOctober 16, 2024 | finance.yahoo.comQ32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024October 14, 2024 | prnewswire.comRenaissance Technologies LLC Takes $265,000 Position in Q32 Bio Inc. (NASDAQ:QTTB)Renaissance Technologies LLC bought a new position in shares of Q32 Bio Inc. (NASDAQ:QTTB - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 14,764 shares of the company's stock, valuedOctober 13, 2024 | marketbeat.comQ32 Bio (NASDAQ:QTTB) Shares Up 4.8% - What's Next?Q32 Bio (NASDAQ:QTTB) Shares Up 4.8% - Here's What HappenedOctober 8, 2024 | marketbeat.comQ32 Bio Inc. (NASDAQ:QTTB) Given Consensus Rating of "Buy" by BrokeragesQ32 Bio Inc. (NASDAQ:QTTB - Get Free Report) has earned an average rating of "Buy" from the six analysts that are currently covering the firm, MarketBeat reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The averageOctober 6, 2024 | marketbeat.comEnsign Peak Advisors Inc Purchases 38,750 Shares of Q32 Bio Inc. (NASDAQ:QTTB)Ensign Peak Advisors Inc increased its position in Q32 Bio Inc. (NASDAQ:QTTB - Free Report) by 150.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 64,481 shares of the company's stock after acquiring an additional 38,7September 29, 2024 | marketbeat.comBank of New York Mellon Corp Invests $315,000 in Q32 Bio Inc. (NASDAQ:QTTB)Bank of New York Mellon Corp bought a new stake in Q32 Bio Inc. (NASDAQ:QTTB - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 17,569 shares of the company's stock, valued at approximately $315,000. Bank of NSeptember 26, 2024 | marketbeat.comQ32 Bio (NASDAQ:QTTB) Trading Down 3.7%Q32 Bio (NASDAQ:QTTB) Trading Down 3.7%September 23, 2024 | marketbeat.comQ32 BIO INC. O.N. (DB0.BE)September 20, 2024 | nz.finance.yahoo.com Get Q32 Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for QTTB and its competitors with MarketBeat's FREE daily newsletter. Email Address Do this Before Elon’s Reveal on January 22nd (Ad)Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen. I urge you to watch this video now. QTTB Media Mentions By Week QTTB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. QTTB News Sentiment▼-0.040.71▲Average Medical News Sentiment QTTB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. QTTB Articles This Week▼332▲QTTB Articles Average Week Get Q32 Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for QTTB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Nkarta News Today Checkpoint Therapeutics News Today scPharmaceuticals News Today Zura Bio News Today Cidara Therapeutics News Today Ventyx Biosciences News Today TScan Therapeutics News Today Seres Therapeutics News Today Nanobiotix News Today FitLife Brands News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:QTTB) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Q32 Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
